Clinical prediction models for inhibitor development in severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 7, Issue SUPPL. 1, 2009, Pages 98-102

  van den Berg, H Marijke ^a   Chalmers, E A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Factor VIII inhibitor; Hemophilia A; Intensive treatment; Survey

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; CONCURRENT INFECTION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; EARLY INTERVENTION; ELECTIVE SURGERY; ETHNIC DIFFERENCE; FAMILY HISTORY; GENETIC DISORDER; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; THERAPY DELAY;

AUTOANTIBODIES; DATA COLLECTION; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; HEMOPHILIA A; HUMANS; PRECIPITATING FACTORS; PROGNOSIS; RISK FACTORS;

EID: 67849128717     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03437.x     Document Type: Review

References (28)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-59.
2. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
4. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tudderham EG, Oldenburg J. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
5. Schroder J, El-Maarri O, Schwaab R, Muller CR, Oldenburg J. Factor VIII intron-1 inversion: Frequency and inhibitor prevalence. J Thromb Haemost 2006; 4: 1141-3.
6. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
7. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
8. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study. Blood 2007; 109: 4693-7.
9. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
10. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
11. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
12. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-79.
13. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
14. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
15. Morado M, Villar A, Jimenez YV, Quintana M, Hernandez NF. Prophylactic treatment effects on inhibitor risk: Experience in one centre. Haemophilia 2005; 11: 79-83.
16. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-27.
17. Avest PC, Fischer K, mancuso ME, Santogostina E, Yuste VJ, Van den Berg HM, Van der BOM JG, on behalf of the CANAL Study group. Risk stratification for inhibitor development at first treatment for severe hemophilia: A tool for clinical practise. J Thromb Haemost 2008; 6: 2048-54.
18. Gouw SC, van den Berg HM, Le CS, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multi-center cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
19. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-5.
20. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007; 136: 12-25.
21. Pollman H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single centre study. Eur J Pediatr 1999; 158: 166-70.
22. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Preijs R, de Kleijn P, Grobbee DE, van den Berg HM. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
23. Van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophili: The role of the first joint bleed. Hameophilia 2005; 11: 438-43.
24. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
25. White GC. Prediction of inhibitors in hemophilia. J Thromb Haemost 2008; 6: 2045-47.
26. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 37: 3739-45.
27. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
28. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.